Renaissance Technologies’s Arcutis Biotherapeutics ARQT Stock Holding History

Renaissance Technologies’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.53M	Sell	58,399 -382,600	-87%	-$8.91M	﹤0.01%	2110
2026 Q1	$10.4M	Buy	440,999 +167,000	+61%	+$4.26M	0.02%	948
2025 Q4	$7.96M	Buy	+273,999	New	+$7.01M	0.01%	1038
2025 Q2	–	Sell	-21,799	Closed	-$341K	–	3544
2025 Q1	$341K	Buy	21,799 +10,700	+96%	+$151K	﹤0.01%	2881
2024 Q4	$155K	Sell	11,099 -181,000	-94%	-$1.98M	﹤0.01%	3222
2024 Q3	$1.79M	Buy	+192,099	New	+$1.9M	﹤0.01%	2098
2024 Q1	–	Sell	-395,100	Closed	-$1.28M	–	3689
2023 Q4	$1.28M	Buy	+395,100	New	+$1.07M	﹤0.01%	2242
2022 Q4	–	Sell	-65,000	Closed	-$1.24M	–	4099
2022 Q3	$1.24M	Buy	65,000 +54,200	+502%	+$1.23M	﹤0.01%	2366
2022 Q2	$230K	Buy	+10,800	New	+$222K	﹤0.01%	3584
2020 Q3	–	Sell	-27,700	Closed	-$838K	–	3359
2020 Q2	$838K	Buy	+27,700	New	+$801K	﹤0.01%	2634

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies's ARQT Position: Q2 2026 in Review

Renaissance Technologies reduced its Arcutis Biotherapeutics (ARQT) stake by 87% in Q2 2026, selling an estimated $8.91M and leaving 58,399 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Renaissance Technologies first reported a position in ARQT in Q2 2020 and has held it in 10 quarters since. The position peaked at $10.4M in Q1 2026. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Renaissance Technologies held 58,399 shares of Arcutis Biotherapeutics worth $1.53M as of Q2 2026.
Renaissance Technologies sold 382,600 Arcutis Biotherapeutics shares in Q2 2026, an estimated $8.91M.
Arcutis Biotherapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2110 holding.
Renaissance Technologies first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 10 quarters since.
Renaissance Technologies's Arcutis Biotherapeutics position peaked at $10.4M in Q1 2026.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.